Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Open-label, Controlled, Dose-elevation, Multicenter Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer

NCT00040391 is registered in ClinicalTrials.gov with Celgene Corporation as lead sponsor.

NCT NCT00040391
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00040391 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Open-label, Controlled, Dose-elevation, Multicenter Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer
Lead sponsor
Celgene Corporation
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2002
Completion date
Not reported
Enrollment
Not reported
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal neoplasms, diarrhea